EsoGuard has commercial coverage but survives on dilutive equity; Medicare LCD decision determines whether the reimbursement foundation holds

Lucid Diagnostics is a commercial-stage company whose lead product, EsoGuard, is an approved test that detects early precancerous changes in the esophagus in patients with acid reflux, and the company's survival depends on whether Medicare coverage expands beyond current commercial plan support.

Lucid Diagnostics built EsoGuard, a swallowed capsule-based DNA test detecting Barrett's esophagus precancer in GERD patients before it progresses to esophageal cancer, and the entire commercial case rests on Medicare coverage for a patient population that skews older. Multiple commercial health plans now cover the test, and a VA contract at $1,938 per test signals pricing power, but sub-$2M quarterly revenue against $13.4M burn makes the Medicare LCD the sole path to a self-sustaining business. A negative LCD outcome would likely require additional dilutive financing before any alternative coverage pathway matures.